NICE backs Celgene’s Revlimid for chemo-free lymphoma therapyNICE has backs Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a Share XNICE backs Celgene’s Revlimid for chemo-free lymphoma therapyhttps://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/
Epizyme eyes lucrative use for newly-launched TazverikUS biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the Share XEpizyme eyes lucrative use for newly-launched Tazverikhttps://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Janssen to develop Darzalex successor with GenmabJanssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it Share XJanssen to develop Darzalex successor with Genmabhttps://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/
FDA approves Roche’s $90,000 lymphoma combinationThe FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – Share XFDA approves Roche’s $90,000 lymphoma combinationhttps://pharmaphorum.com/news/fda-approves-roches-90000-lymphoma-combination/
Morphosys to take on CAR-Ts in NHL with promising antibodyGermany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a Share XMorphosys to take on CAR-Ts in NHL with promising antibodyhttps://pharmaphorum.com/news/morphosys-to-take-on-car-ts-in-nhl-with-promising-antibody/
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOIt has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership Share XGilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOhttps://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/
